Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants

References

• Fauchier L, Philippart R, Clementy N. How to define valvular atrial fibrillation? Arch Cardiovasc Dis. 2015;108(10):530–539.
   PubMed Web of Science ®Google Scholar
• Silva R. Novel oral anticoagulants in non-valvular atrial fibrillation. CHAMC. 2014;12(1):3–8.
   Google Scholar
• Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, et al. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis. 2013;2013:1.
   Google Scholar
• Patel P, Pandya J, Goldberg M. NOACs vs warfarin for stroke prevention in nonvalvular atrial fibrillation. Cureus. 2017;9(6):e1395.
   PubMed Web of Science ®Google Scholar
• Gilligan AM, Franchino-Elder J, Song X, et al. Comparison of all-cause costs and healthcare resource use among patients with newly diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants. Curr Med Res Opin. 2018;34(2):285–295.
   PubMed Web of Science ®Google Scholar
• Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the US adult population. Am J Cardiol. 2013;112(8):1142–1147.
   PubMed Web of Science ®Google Scholar
• Marinigh R, Lip GY, Fiotti N, et al. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol. 2010;56(11):827–837.
   PubMed Web of Science ®Google Scholar
• Ovbiagele B, Goldstein LB, Higashida RT, et al. Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association. Stroke. 2013;44(8):2361.
   PubMed Web of Science ®Google Scholar
• Kim CK, Jung S, Yoon BW. Practical issues to prevent stroke associated with non-valvular atrial fibrillation. J Stroke. 2013;15(3):144–152.
   PubMed Web of Science ®Google Scholar
• Gattellari M, Worthington JM, Zwar NA, et al. The management of non-valvular atrial fibrillation (NVAF) in Australian general practice: bridging the evidence-practice gap. A national, representative postal survey. BMC Fam Pract. 2008;9(1):62.
   PubMedGoogle Scholar
• Inoue H, Nozawa T, Hirai T, et al. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J. 2006;70(6):651–656.
   PubMed Web of Science ®Google Scholar
• Amin A, Keshishian A, Trocio J, et al. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Curr Med Res Opin. 2017;33(9):1595–1604.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation antithrombotic therapy in atrial fibrillation. Ann Intern Med. 2007;146(12):857–867.
   PubMed Web of Science ®Google Scholar
• Amin A, Keshishian A, Vo L, et al. Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. J Med Econ. 2018;21(3):244–253.
   PubMed Web of Science ®Google Scholar
• Lauffenburger JC, Farley JF, Gehi AK, et al. Effectiveness and safety of dabigatran and warfarin in real‐world US patients with non‐valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc. 2015;4(4):e001798.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Antz M, Bowrin K, et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Curr Med Res Opin. 2016;32(12):2047–2053.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• García-Lledó A, Mur JL, Recena JB, et al. Nonvalvular atrial fibrillation: the problem of an undefined definition. Rev Esp Cardiol (Engl Ed). 2014;67(08):670–671.
   PubMedGoogle Scholar
• Martins RP, Galand V, Colette E, et al. Defining nonvalvular atrial fibrillation: a quest for clarification. Am Heart J. 2016;178:161–167.
   PubMed Web of Science ®Google Scholar
• Molteni M, Polo Friz H, Primitz L, et al. The definition of valvular and non-valvular atrial fibrillation: results of a physicians' survey. Europace. 2014;16(12):1720–1725.
   PubMed Web of Science ®Google Scholar
• Francis K, Yu C, Alvrtsyan H, et al. Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2015;31(12):2189–2195.
   PubMed Web of Science ®Google Scholar
• Gilligan AM, Gandhi P, Song X, et al. All- cause, stroke-, and bleed-specific healthcare costs: comparison among patients with non-valvular atrial fibrillation (NVAF) newly treated with dabigatran or warfarin. Am J Cardiovasc Drugs. 2017;17(6):481–492.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Luo X, Gupta K, et al. Effect of apixaban versus warfarin use on health care resource utilization and costs among elderly patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2017;23(11):1191–1201.
   PubMed Web of Science ®Google Scholar
• Laliberté F, Cloutier M, Crivera C, et al. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users. Adv Ther. 2015;32(3):216–227.
   PubMed Web of Science ®Google Scholar
• Amin A, Keshishian A, Xie L, et al. Comparison of short-term bleeding-related health care utilization and costs among treatment-naïve nonvalvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. Chest. 2015;148(4):65A.
   Web of Science ®Google Scholar
• Wisløff T, Hagen G, Klemp M. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. Pharmacoeconomics. 2014;32(6):601–612.
   PubMed Web of Science ®Google Scholar
• Cubanski J, Swoope C, Boccuti C, et al. kff.org [Internet]. A primer on Medicare: key facts about the Medicare program and the people it covers. San Francisco (CA): The Henry J. Kaiser Family Foundation; c1948–2019; 2015 [cited 2019 Mar 13]. Available from: http://files.kff.org/attachment/report-a-primer-on-medicare-key-facts-about-the-medicare-program-and-the-people-it-covers
   Google Scholar
• cms.gov [Internet]. On its 50th anniversary, more than 55 million Americans covered by Medicare; Baltimore (MD): Centers for Medicare and Medicaid Services, c1965–2019; 28 Jul 2015 [cited 2019 Mar 13]. Available from: https://www.cms.gov/newsroom/press-releases/its-50th-anniversary-more-55-million-americans-covered-medicare
   Google Scholar
• bls.gov [Internet]. Inflation and prices calculators. Washington (DC): US Department of Labor Bureau of Labor Statistics; c1884–2019. [cited 2019 Mar 13]. Available from: http://www.bls.gov/data/#prices
   Google Scholar
• Verzillo S, Berta P, Bossi M. CEM: a SAS macro to perform coarsened exact matching. J Stat Comput Simul. 2017;87(2):227–238.
   Web of Science ®Google Scholar
• Seiter K, Latremouille-Viau D, Guerin A, et al. Burden of infections among chronic myeloid leukemia patients receiving dasatinib or nilotinib: a real-world retrospective healthcare claims study in the United States. Adv Ther. 2018;35(10):1671–1685.
   PubMed Web of Science ®Google Scholar
• Kılıç S, Kemal HS, Yüce Eİ, et al. Comparison of warfarin use in terms of efficacy and safety in two different polyclinics. Anatolian J Cardiol. 2017;18(5):328.
   Web of Science ®Google Scholar
• Khan TI, Kamali F, Kesteven P, et al. The value of education and self‐monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol. 2004;126(4):557–564.
   PubMed Web of Science ®Google Scholar
• Shikdar S, Bhattacharya PT. International normalized ratio (INR). StatPearls Publishing; 2019 [cited 2019 Mar 22]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507707/
   Google Scholar
• Bancroft T, Lim J, Wang C, et al. Health care resource utilization, costs, and persistence in patients newly diagnosed as having nonvalvular atrial fibrillation and newly treated with dabigatran versus warfarin in the United States. Clin Ther. 2016;38(3):545–556.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Vital signs. African American health [cited 2019 Aug 15]. Available from: https://www.cdc.gov/vitalsigns/pdf/2017-05-vitalsigns.pdf.
   Google Scholar
• Jain R, Fu AC, Lim J, et al. Health care resource utilization and costs among newly diagnosed and oral anticoagulant-naive nonvalvular atrial fibrillation patients treated with dabigatran or warfarin in the United States. J Manag Care Spec Pharm. 2018;24(1):73–82.
   PubMed Web of Science ®Google Scholar
• Gilligan AM, Franchino-Elder J, Song X, et al. Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin. Expert Rev Pharmacoecon Outcomes Res. 2019;19(2):203–212.
   PubMed Web of Science ®Google Scholar
• Tepper PG, Mardekian J, Masseria C, et al. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. PLOS One. 2018;13(11):e0205989.
   PubMed Web of Science ®Google Scholar
• Amin A, Keshishian A, Trocio J, et al. A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the US Medicare population. JMCP. 2018;24(9):911–920.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Luo X, Gupta K, et al. All-Cause, stroke/systemic embolism–, and major bleeding-related health-care costs among elderly patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Clin Appl Thromb Hemost. 2018;24(4):602–611.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Baro E, Zhang R, et al. Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132(5):596–604.e11.
   PubMed Web of Science ®Google Scholar
• Mues KE, Liede A, Liu J, et al. Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US. CLEP. 2017;9:267.
   Google Scholar